Cargando…

End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation

BACKGROUND: Hepatitis B surface antigen (HBsAg) loss, namely, the functional cure, can be achieved through the pegylated interferon (PEG-IFN)-based therapy. However, it is an unignorable fact that a small proportion of patients who achieved functional cure develop HBsAg reversion (HRV) and the relat...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yifei, Han, Jiajia, Zhang, Yongmei, Jin, Chengmeng, Zhang, Yao, He, Jingjing, Chen, Shiqi, Guo, Yue, Lin, Yanxue, Li, Fahong, Yang, Feifei, Shen, Zhongliang, Mao, Richeng, Zhu, Haoxiang, Zhang, Jiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998526/
https://www.ncbi.nlm.nih.gov/pubmed/36909726
http://dx.doi.org/10.3389/fcimb.2023.1120300
_version_ 1784903483905802240
author Guo, Yifei
Han, Jiajia
Zhang, Yongmei
Jin, Chengmeng
Zhang, Yao
He, Jingjing
Chen, Shiqi
Guo, Yue
Lin, Yanxue
Li, Fahong
Yang, Feifei
Shen, Zhongliang
Mao, Richeng
Zhu, Haoxiang
Zhang, Jiming
author_facet Guo, Yifei
Han, Jiajia
Zhang, Yongmei
Jin, Chengmeng
Zhang, Yao
He, Jingjing
Chen, Shiqi
Guo, Yue
Lin, Yanxue
Li, Fahong
Yang, Feifei
Shen, Zhongliang
Mao, Richeng
Zhu, Haoxiang
Zhang, Jiming
author_sort Guo, Yifei
collection PubMed
description BACKGROUND: Hepatitis B surface antigen (HBsAg) loss, namely, the functional cure, can be achieved through the pegylated interferon (PEG-IFN)-based therapy. However, it is an unignorable fact that a small proportion of patients who achieved functional cure develop HBsAg reversion (HRV) and the related factors are not well described. METHODS: A total of 112 patients who achieved PEG-IFN-induced HBsAg loss were recruited. HBV biomarkers and biochemical parameters were examined dynamically. HBV RNA levels were assessed in the cross-sectional analysis. The primary endpoint was HRV, defined as the reappearance of HBsAg after PEG-IFN discontinuation. RESULTS: HRV occurred in 17 patients during the follow-up period. Univariable analysis indicated that hepatitis B e antigen (HBeAg) status, different levels of hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc) at the end of PEG-IFN treatment (EOT) were significantly associated with the incidence of HRV through using the log-rank test. Additionally, time-dependent receiver operating characteristic (ROC) analysis showed that the anti-HBs was superior to anti-HBc in predictive power for the incidence of HRV during the follow-up period. Multivariable Cox proportional hazard analysis found that anti-HBs ≥1.3 log(10)IU/L (hazard ratio (HR), 0.148; 95% confidence interval (CI), 0.044-0.502) and HBeAg negativity (HR, 0.183; 95% CI, 0.052-0.639) at EOT were independently associated with lower incidence of HRV. Cross-sectional analysis indicated that the HBV RNA levels were significantly correlated with the HBsAg levels in patients with HRV (r=0.86, p=0.003). CONCLUSIONS: EOT HBeAg negativity and anti-HBs ≥1.3 log(10)IU/L identify the low risk of HRV after PEG-IFN discontinuation.
format Online
Article
Text
id pubmed-9998526
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99985262023-03-11 End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation Guo, Yifei Han, Jiajia Zhang, Yongmei Jin, Chengmeng Zhang, Yao He, Jingjing Chen, Shiqi Guo, Yue Lin, Yanxue Li, Fahong Yang, Feifei Shen, Zhongliang Mao, Richeng Zhu, Haoxiang Zhang, Jiming Front Cell Infect Microbiol Cellular and Infection Microbiology BACKGROUND: Hepatitis B surface antigen (HBsAg) loss, namely, the functional cure, can be achieved through the pegylated interferon (PEG-IFN)-based therapy. However, it is an unignorable fact that a small proportion of patients who achieved functional cure develop HBsAg reversion (HRV) and the related factors are not well described. METHODS: A total of 112 patients who achieved PEG-IFN-induced HBsAg loss were recruited. HBV biomarkers and biochemical parameters were examined dynamically. HBV RNA levels were assessed in the cross-sectional analysis. The primary endpoint was HRV, defined as the reappearance of HBsAg after PEG-IFN discontinuation. RESULTS: HRV occurred in 17 patients during the follow-up period. Univariable analysis indicated that hepatitis B e antigen (HBeAg) status, different levels of hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc) at the end of PEG-IFN treatment (EOT) were significantly associated with the incidence of HRV through using the log-rank test. Additionally, time-dependent receiver operating characteristic (ROC) analysis showed that the anti-HBs was superior to anti-HBc in predictive power for the incidence of HRV during the follow-up period. Multivariable Cox proportional hazard analysis found that anti-HBs ≥1.3 log(10)IU/L (hazard ratio (HR), 0.148; 95% confidence interval (CI), 0.044-0.502) and HBeAg negativity (HR, 0.183; 95% CI, 0.052-0.639) at EOT were independently associated with lower incidence of HRV. Cross-sectional analysis indicated that the HBV RNA levels were significantly correlated with the HBsAg levels in patients with HRV (r=0.86, p=0.003). CONCLUSIONS: EOT HBeAg negativity and anti-HBs ≥1.3 log(10)IU/L identify the low risk of HRV after PEG-IFN discontinuation. Frontiers Media S.A. 2023-02-24 /pmc/articles/PMC9998526/ /pubmed/36909726 http://dx.doi.org/10.3389/fcimb.2023.1120300 Text en Copyright © 2023 Guo, Han, Zhang, Jin, Zhang, He, Chen, Guo, Lin, Li, Yang, Shen, Mao, Zhu and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Guo, Yifei
Han, Jiajia
Zhang, Yongmei
Jin, Chengmeng
Zhang, Yao
He, Jingjing
Chen, Shiqi
Guo, Yue
Lin, Yanxue
Li, Fahong
Yang, Feifei
Shen, Zhongliang
Mao, Richeng
Zhu, Haoxiang
Zhang, Jiming
End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation
title End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation
title_full End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation
title_fullStr End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation
title_full_unstemmed End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation
title_short End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation
title_sort end-of-treatment anti-hbs levels and hbeag status identify durability of hbsag loss after peg-ifn discontinuation
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998526/
https://www.ncbi.nlm.nih.gov/pubmed/36909726
http://dx.doi.org/10.3389/fcimb.2023.1120300
work_keys_str_mv AT guoyifei endoftreatmentantihbslevelsandhbeagstatusidentifydurabilityofhbsaglossafterpegifndiscontinuation
AT hanjiajia endoftreatmentantihbslevelsandhbeagstatusidentifydurabilityofhbsaglossafterpegifndiscontinuation
AT zhangyongmei endoftreatmentantihbslevelsandhbeagstatusidentifydurabilityofhbsaglossafterpegifndiscontinuation
AT jinchengmeng endoftreatmentantihbslevelsandhbeagstatusidentifydurabilityofhbsaglossafterpegifndiscontinuation
AT zhangyao endoftreatmentantihbslevelsandhbeagstatusidentifydurabilityofhbsaglossafterpegifndiscontinuation
AT hejingjing endoftreatmentantihbslevelsandhbeagstatusidentifydurabilityofhbsaglossafterpegifndiscontinuation
AT chenshiqi endoftreatmentantihbslevelsandhbeagstatusidentifydurabilityofhbsaglossafterpegifndiscontinuation
AT guoyue endoftreatmentantihbslevelsandhbeagstatusidentifydurabilityofhbsaglossafterpegifndiscontinuation
AT linyanxue endoftreatmentantihbslevelsandhbeagstatusidentifydurabilityofhbsaglossafterpegifndiscontinuation
AT lifahong endoftreatmentantihbslevelsandhbeagstatusidentifydurabilityofhbsaglossafterpegifndiscontinuation
AT yangfeifei endoftreatmentantihbslevelsandhbeagstatusidentifydurabilityofhbsaglossafterpegifndiscontinuation
AT shenzhongliang endoftreatmentantihbslevelsandhbeagstatusidentifydurabilityofhbsaglossafterpegifndiscontinuation
AT maoricheng endoftreatmentantihbslevelsandhbeagstatusidentifydurabilityofhbsaglossafterpegifndiscontinuation
AT zhuhaoxiang endoftreatmentantihbslevelsandhbeagstatusidentifydurabilityofhbsaglossafterpegifndiscontinuation
AT zhangjiming endoftreatmentantihbslevelsandhbeagstatusidentifydurabilityofhbsaglossafterpegifndiscontinuation